Chewy's Raised FY26 Guidance Offsets Insider-Selling Overhang

What happened

Seeking Alpha's October 11 article highlights Chewy's resilient fundamentals, with Autoship driving 85% of revenue and management raising FY26 guidance to $13.46–$13.57B with EBITDA margins of 6.7–6.8%, above the previously expected 6.0%. This follows a period of stock weakness attributed to insider-selling headlines and a tough discretionary environment, as captured in the DeepValue master report. The master report's base case assumed 6.0% adjusted EBITDA margin, so the new guidance suggests better-than-expected operating leverage. However, the master report also flagged persistent insider selling (CTO's 10b5-1 plan through December 2026) and a low-growth category backdrop, which remain risks. The valuation of ~7x FY27 EBITDA is depressed relative to growth, but the stock's multiple has compressed from over 38x EV/EBITDA at the time of the master report.

Implication

The raised FY26 guidance addresses the master report's key condition for a higher rating, as EBITDA margins are now expected well above 6.0%. Confirmation of Autoship penetration at 85% (up from 83.9% in Q3 FY25) supports recurring revenue resilience. However, the stock's discount to historical multiples may persist if executive sales continue and discretionary spending stays soft. A disciplined entry near $24 (the master report's attractive level) remains prudent, with upside to $32 if sentiment improves. Failure to maintain gross margin expansion or a slowdown in customer growth would invalidate the bullish case.

Thesis delta

The investment thesis has strengthened on the fundamental side: management's FY26 guidance of 6.7–6.8% EBITDA margin exceeds the master report's threshold of 6.0%, confirming operating leverage. However, the thesis's sentiment headwind from insider selling remains unaddressed, and the stock's reaction to guidance will depend on whether the market looks past that overhang. The overall rating improves from 'Potential Buy' to a stronger 'Buy' if the valuation remains below $30, but we maintain a cautious stance until insider sales abate.